Respiratory Syncytial Virus in Transplant: Stopping the Short-Term Spread, Solving the Longer-Term Problems
Emerging Transplant Infections: Clinical Challenges and Implications, Page: 725-741
2021
- 1Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures1
- Readers1
Book Chapter Description
Respiratory syncytial virus (RSV) causes significant morbidity and mortality in immunocompromised hosts with particular burden among allogeneic hematopoietic stem cell transplant and lung transplant recipients. Affected patients have a substantial risk of secondary infection, ICU admission, or death. Improved diagnostic testing with better sensitivity has given new insights into the epidemiology of disease. In particular, it has highlighted the issue of nosocomial transmission and hospital outbreaks. These can be challenging to manage. Currently, treatment options include ribavirin and immunoglobulin replacement. Definitive evidence of the efficacy of this approach is limited. Given the significant impact of this common infection in this at-risk patient population, research is ongoing into new strategies for prevention and treatment. These range from new antiviral therapies targeting different steps of the replication cycle to monoclonal antibodies and vaccines.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85149489509&origin=inward; http://dx.doi.org/10.1007/978-3-030-25869-6_30; https://link.springer.com/10.1007/978-3-030-25869-6_30; https://link.springer.com/content/pdf/10.1007/978-3-030-25869-6_30; https://dx.doi.org/10.1007/978-3-030-25869-6_30; https://link.springer.com/referenceworkentry/10.1007/978-3-030-25869-6_30
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know